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LETTERS TO THE EDITOR 
Unethical Placebo Assignment in Clinical 
Trials of Thrombolysis 
Marcia Angell, Executive Editor of the New England Journal of 
Medicine, recently argued that "the most frequent types of unethi-
cal research occurring today involve obtaining informed consent as 
a legalism, without truly informing the subjects, and inappropriately 
using a placebo group in a clinical trial" (1). 
From Figure 1, showing the chronologic relation of the main 
placebo-controlled trials (2-16) of intravenous thrombolysis in acute 
myocardial infarction, one can readily realize that the research 
recently reported in the Journal by Munkvad and colleagues (16) is 
of this type. 
Between 1986 and 1987, after publication of the results of some 
large studies (2-5) (arrows in Figure 1), it became evident that 
thrombolysis is a life-saving treatment for patients with acute 
myocardial infarction. For this reason, some investigators ended 
their placebo-controlled trials sooner than planned (6,8), or at least 
modified the study design (10). 
Unfortunately, this sensitive behavior has not been shared by all, 
including the Esbjerg investigators (16), who began to randomize 
patients to placebo versus recombinant tissue-type plasminogen 
Figure 1. Chronologic relation of placebo-controlled trials of intra-
venous thrombolysis in acute myocardial infarction. Arrows indicate 
the time of publication of the studies that demonstrated the effec-
tiveness of thrombolysis. Horizontal bars indicate the period of 
patient enrollment in the other studies. For the Anglo-Scandinavian 
Study of Early Thrombolysis (ASSET) study, A indicates the 
enrollment in the United Kingdom and Norway, B in Sweden and C 
in Denmark. The references are as follows: Yusuf et al. (2), GISSI 
(3), ISAM (4), ISIS-2 (5), Western Washington (6), Auckland (7), 
Johns Hopkins (8), TICO (9), Australian National (NAT.) (10), 
AIMS (11), ECSG-V (12), TPAT (13), ASSET (14), TEAHAT (15), 
Esbjerg (16). SK = streptokinase; tPA = tissue plasminogen acti-
vator. 
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activator (rt-PA) on October I, 1987, which is exceedingly late, and 
continued the trial to the planned end on June 1, 1988. 
A short time ago, I noted (17) that the investigators of the 
Thrombolysis Early in Acute Heart Attack Trial (TEAHAn study 
(15), completed in April 1988, were the very last to have deliberately 
deprivated patients with acute myocardial infarction of a potentially 
helpful thrombolytic treatment. Now the Esbjerg investigators hold 
this unpleasant record. I hope that it will not be exceeded once 
more, or at least that scientific journals will no more reward such 
unethical research through publication. 
ENRICO GERACI, MD 
Dil'ision of Cardiology 
V. Cerl'el/o Hospital 
Via De Gasperi 30 
90146 Palermo. Italy 
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